Lynn Kirkpatrick
Virginia Commonwealth University
22 Papers
105 Citations
Lynn Kirkpatrick is an academic researcher from Virginia Commonwealth University. The author has contributed to research in topics: KRAS & Pleckstrin homology domain. The author has an hindex of 11, co-authored 21 publications.
Chat about Author
Papers
•Journal Article
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
Nathan T. Ihle,Ryan Williams,Sherry Chow,Wade Chew,Margareta Berggren,Gillian Paine-Murrieta,Daniel J. Minion,Robert J. Halter,Peter Wipf,Robert T. Abraham,Lynn Kirkpatrick,Garth Powis +11 more
TL;DR: The results show that PX-866 is a biologically stable broad-spectrum PtdIns-3-kinase inhibitor with good pharmacokinetics that causes prolonged inhibition of Ptdins-3,kinase signaling in human tumor xenografts.
340
•Journal Article
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α
TL;DR: It is reported that PX-478 given to mice suppresses HIF-1α levels in HT-29 human colon cancer xenografts and inhibits the expression of Hif-1 target genes including vascular endothelial growth factor and the glucose transporter-1.
Dynamic Contrast-Enhanced and Diffusion MRI Show Rapid and Dramatic Changes in Tumor Microenvironment in Response to Inhibition of HIF-1α Using PX-478
Bénédicte F. Jordan,Bénédicte F. Jordan,Matthew L. Runquist,Natarajan Raghunand,Amanda F. Baker,Ryan Williams,Lynn Kirkpatrick,Garth Powis,Robert J. Gillies +8 more
TL;DR: PX-478 induced a dramatic reduction in tumor blood vessel permeability within 2 hours after treatment, which returned to baseline by 48 hours, which is the earliest significant response of ADC to therapy yet reported.
144
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Ramesh K. Ramanathan,James L. Abbruzzese,Tomislav Dragovich,Lynn Kirkpatrick,Jose Guillen,Amanda F. Baker,Linda Pestano,Sylvan B. Green,Daniel D. Von Hoff +8 more
TL;DR: PX-12 does not appear to be active in unselected patients with previously treated advanced pancreatic cancer, and the study was terminated early due to the lack of significant antitumor activity and unexpectedly low baseline Trx-1 levels.
114
Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice
Jörg J. Jacoby,Baruch Erez,Maria V. Korshunova,Ryan R. Williams,Kazuhisa Furutani,Osamu Takahashi,Lynn Kirkpatrick,Scott M. Lippman,Garth Powis,Michael S. O'Reilly,Roy S. Herbst +10 more
TL;DR: It is demonstrated that the PX-478, HIF-1&agr; inhibitor, had significant antitumor activity against two orthotopic models of lung adenocarcinomas and two models of SCLC.
76